A study to assess the safety and efficacy of AZD7789 in participants with advanced or metastatic solid cancer

Trial Identifier: D9570C00001
Sponsor: AstraZeneca
NCTID:: NCT04931654
Start Date: September 2021
Primary Completion Date: July 2025
Study Completion Date: July 2025
Condition: Lung Cancer; Gastric Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CA, AB Edmonton, AB, CA, T6G 1Z2
CA, ON Toronto, ON, CA, M5G 2M9
CN Beijing, CN, 100142
CN Guangzhou, CN, 510060
ES Barcelona, ES, 08035
ES Madrid, ES, 28027
FR Bordeaux, FR, 33076
FR Marseille, FR, 13385
FR Rennes, FR, 35000
FR Villejuif Cedex, FR, 94805
GE Tbilisi, GE, 0112
JP Chuo-ku, JP, 104-0045
JP Kashiwa, JP, 277-8577
JP Sendai-shi, JP, 980-0873
MD Chisinau, MD, MD-2025
NL Amsterdam, NL, 1066 CX
TR Adana, TR, 01060
TR Ankara, TR, 06010
TR Ankara, TR, 06200
TR Ankara, TR, 06800
TR Bornova-Izmir, TR, 35100
TR Edirne, TR, 22030
TR Istanbul, TR, 34722
TR Karsiyaka, TR, 35575
US, GA Atlanta, GA, US, 30322
US, IN Fort Wayne, IN, US, 46804
US, NY New York, NY, US, 10029
US, TN Nashville, TN, US, 37203